Tag: Xeljanz

May 4, 2017 Off

FDA takes Pfizer’s sNDA for psoriatic arthritis drug

By Dino Mustafić

United States Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Pfizer’s Xeljanz (tofacitinib citrate) 5 mg twice daily (BID) and XeljanzXR extended release 11 mg once daily use the treatment of adult patients with active psoriatic arthritis (PsA).